Author: Madison Esely-Kohlman

Repurposing (repositioning, re-profiling, or re-tasking) a drug potentially saves years of costly testing from going to waste and potentially providing a higher chance of success.…

As part of our Meet the Scientist series, we introduce you to one of our most notable product experts, Stephanie Helmstetter.

“Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an...

As part of our Meet the Scientist series, we introduce you to one of our most notable Enzyme Inhibition experts, Lois Haupt.

We are thrilled to welcome you to the brand new XenoTech website! The reconstruction project is a massive overhaul of over 1,000 pages carefully recrafted…

In preclinical development, a drug will be evaluated for potential to cause a drug-drug interaction (DDI) using in vitro experiments and then calculations that...

The main goal of preclinical toxicokinetic (TK) studies is to establish a correlation between a candidate compound’s concentration or dose...

“Given the rapid spread of COVID-19 and its relatively high mortality, filling the gap for coronavirus-specific drugs is urgent. […]...

Drug metabolism and pharmacokinetics (DMPK) is a core discipline in drug development that considers the biotransformation of a drug compound...

We have welcomed a new consultant to the team! Dr. Pallavi Limaye now serves as a Director in the Scientific...

Highlights from the recent webinar presented by our newest expert consultant, Dr. Pallavi Limaye In her recent webinar (now available for...

We are offering a brand new cell line to assist researchers in the fight against COVID-19.The cell line (JCRB1819), developed...

The main aim of drug development is to get a compound that has a therapeutic effect into the form of...

In its most recent in vitro drug interaction guidance update, the US Food and Drug Administration (FDA) emphasized harmony with the...

1. Collect high-quality data to make informed, confident go/no go decisions for moving your drug candidate forward If you need...

Systemic clearance, denoting how much drug is cleared from a volume of blood per unit of time, is of critical...

Beyond the need for evidence that a drug works, Food and Drug Administration (FDA) and other regulatory bodies around the...

Regulatory authorities publish updated guidance documents that share their expectations for endpoints and test systems with drug developers, but sometimes it is difficult to...

Though there is no ‘roadmap’ spelling out required studies to achieve regulatory approval for clinical entry, a drug candidate’s metabolism...

As a drug moves through the development pipeline, it undergoes a rigorous battery of safety assessments to prove it will...

Because each new drug is unique in characteristics, such as chemical structure, mechanism of action, and physicochemical properties, there can...